What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?

Slides:



Advertisements
Similar presentations
Adding Prandial Insulin to Basal Insulin: Key Challenges
Advertisements

What's New in Basal Insulin for Diabetes
Case-Based Examination of Treatment Options in Type 2 Diabetes Management.
Insulin and Incretins: the perfect Partnership?
Diabetic Dyslipidemia in Practice
Updates and Perspectives in Diabetic Dyslipidemia
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
Applying Data to Practice
CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?
Patient Case 1 Peggy Peggy Interactive Case Question.
Faster-Acting Insulins
Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.
SGLT2 Inhibitors: What Do the Data Mean for My Patients?
New Patient-Friendly Options for Managing Insulin Dosing
Modern Strategies for Basal Insulin Use in T2D
Insulin Innovation.
Insulin/GLP-1 Agonist Combinations
Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.
Insulin Intensification Strategies in Later-Stage Type 2 Diabetes Mellitus.
Agenda. Insulin Intensification Strategies: An Expert Perspective from Asia-Pacific.
SGLT2 Inhibitors in Phase 3 Trials
Clinical Advances in Type 2 Diabetes and Cardiovascular Risk
Novel Concentrated Insulins: What Benefits and for Which Patients?
Updates Abound.
Working as a Team for Improved Patient Outcomes in Type 2 Diabetes
Examining CV Effects of Basal Insulin Therapy
Novel Developments & Latest Clinical Results With Long-Acting GLP-1 Receptor Agonists.
Innovative Insulin Combinations: A New strategy for the Person With T2DM.
Goals. Achieving HbA1c Goals: Applying Guidelines to Intensify Therapy in Patients With Diabetes.
Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?
Impacting CV Risk With Diabetes Medications
Impacting CV Risk With Diabetes Medications
GLP-1 Receptor Agonists: How Early Is Appropriate?
Faster-Acting Insulins
Are We Closer to Personalized Medicine in MS?
A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.
Novel Insulin Combinations: What Does the Primary Care Physician Need to Know?
Integrated Diabetes Care: How Can We Make the Best Use of New Technology?
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
A Journal Club on Lipid Management:
Insulin/GLP-1 Agonist Combinations
Insulin Use in Primary Care: Practice Challenges
Insulin Innovation.
Program Goals Overview Glatiramer Acetate 3 Times a Week.
Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus
LEADER One Year On.
Simplifying Insulin Delivery for Better Patient Outcomes in T2D
GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?
Novel Approaches to T1D Management
Better Diabetes Control With Novel Basal Insulins
Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?
Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.
Younger Patients With Type 1 Diabetes: Can We Optimize Their Insulin Therapy?
CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?
Dual SGLT1/SGLT2 Inhibition in T1D
Insulin in Diabetes Management: Effective Patient Selection Is Key
COMBINATIONS AND COFORMULATIONS: THE FUTURE OF INSULIN THERAPY?
Add-On Therapy to Insulin in T1DM Management
Improving Effective Basal Insulin Use in Clinical Practice
Getting PPG Under Control
Emerging Combination Injectable Therapy A New Era in Diabetes Care
Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.
Fixed-Ratio Combination Therapy in T2DM
Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.
The Expanding Role of SGLT Inhibitors Across the Diabetes Spectrum
The Elevated Role of GLP-1 RAs in Diabetes Management: Which Patients Should We Aim For?
Fresh perspectives ON BASAL Insulins in diabetes care
In the Know.
Presentation transcript:

What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?

Program Goals

Program Overview

Intensifying Diabetes Therapy In Patients Already On Basal Insulin: Challenge

"Maximum" Dose of Basal Insulin

Combination Injectable Therapy: Evidence-Based Recommendations

Time From Initiation of Basal Insulin to Intensification in Clinically Eligible Patients*

Treatment for Hyperglycemia Changes Over Time in Patients With T2DM

"Maximum" Dose of Basal Insulin (cont)

Achieving Glycemic Control

Relative Contributions of FPG and PPG to HbA1c

Basal Insulin/GLP-1 RA FRC Agents

LixiLan-L Trial: Key Results

DUAL V: Key Results

CVOTs With GLP-1 RAs

Mechanism of Action of GLP-1 RAs

Nutrition Therapy in Patients With T2DM

Benefits of Adding a GLP-1 RA to Basal Insulin vs Adding Prandial Insulin

Cost-Effectiveness of FRC Therapy: Data From DUAL V

Integrating Basal Insulin/GLP-1 RA FRC Therapy Into Primary Care: Challenges

Basal Insulin/GLP-1 RA FRC Agents

Integrating Basal Insulin/GLP-1 RA FRC Therapy Into Primary Care: Challenges (cont)

Mean Daily Dose of Basal Insulin Significantly Lower With FRC Therapy

Fewer Adverse GI Events With FRC Agents vs GLP-1 RAs

Basal Insulin/GLP-1 RA FRC Agents: Available in Prefilled Pens

Minimizing the Risk of Nausea When Adding a GLP-1 RA to Basal Insulin

Understanding the Role of Basal Insulin/GLP-1 RA FRC Agents In T2DM Management

Using Basal Insulin/GLP-1 RA FRC Therapy in Clinical Practice -- IDegLira

Using Basal Insulin/GLP-1 RA FRC Therapy in Clinical Practice -- IGlarLixi

Switching to Basal Insulin/GLP-1 RA FRC Therapy: Practical Considerations

Switching to Basal Insulin/GLP-1 RA FRC Therapy: Practical Considerations (cont)

IGlarLixi: Method of Administration

Insulin Dose

Basal Insulin/GLP-1 RA FRC Therapy: Future Considerations

Summary

Abbreviations